Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Firm signs OEM agreement with Qualigen Inc. that will allow Endocare to include Qualigen's 15-minute total prostate specific antigen test into Endocare's diagnostic station for urology, firm announces June 4. The five-year agreement specifies one year of exclusivity with the option to extend exclusivity. Integrating Qualigen's PSA test into the workstation will allow patients quicker access to their total PSA scores, which are used in the diagnosis and management of prostate cancer, Endocare says. The new workstation and its associated diagnostic technology were exhibited at the AUA meeting



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts